Boston Scientific Welcomes Launch of Syntax Score Website

Online tools will help physicians determine treatment strategies

NATICK, Mass. and BARCELONA, Spain, May 19 /PRNewswire-FirstCall/ -- Boston
Scientific Corporation (NYSE: BSX) today welcomed the launch of a new website,
www.syntaxscore.com, dedicated to the understanding and use of the SYNTAX
Score(TM), a novel angiographic tool used to measure the complexity of
coronary artery disease. The Company made the announcement at the annual
EuroPCR Scientific Program in Barcelona.

The SYNTAX Score was developed in connection with the SYNTAX trial, the first
randomized, controlled clinical trial to compare percutaneous coronary
intervention (PCI) using the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary
Stent System to coronary artery bypass graft (CABG) surgery in patients with
left main disease and/or significant narrowing of all three coronary arteries
(three-vessel disease). These complex patients are traditionally treated with
CABG and have been excluded from most prior drug-eluting stent clinical
trials. The SYNTAX trial provides important data related to the treatment of
these complex patients and should help physicians make more informed treatment
decisions.

The SYNTAX Score was used in the trial to characterize coronary anatomy based
on nine anatomic criteria, including lesion frequency, complexity and
location; it assigned a score to each patient. Higher SYNTAX Scores indicate
patients with more complex disease and increased treatment challenges.

The new website allows cardiologists and cardiac surgeons to calculate a
patient's SYNTAX Score and create a description of anatomical complexity of
the coronary vasculature that can be used in combination with a physician's
broader clinical judgment to aid in determining the best revascularization
option. The site also includes a detailed tutorial on the use of the SYNTAX
Score calculator, including definitions and example cases, together with
SYNTAX data presentations and publications.

"The SYNTAX Score website will be an important tool to assist with
revascularization strategies in these complex patient populations," said
Patrick W. Serruys, M.D., Ph.D., Chief of Interventional Cardiology,
Thoraxcenter-Erasmus University, Rotterdam, The Netherlands, and chairman of
the SYNTAX trial steering committee. "Having a consistent grading system for
lesion complexity and severity of coronary artery disease allows me to better
evaluate treatment options for my patients. The website's interactive
calculator makes it easier to determine a patient's score and to reference
current clinical data from the SYNTAX trial associated with that score."

The SYNTAX trial will continue to provide important data throughout the life
of the trial (one-, three- and five-year outcomes). As more data become
available, awareness and understanding of the SYNTAX trial will increase as
will the utility of the SYNTAX Score.

"Boston Scientific is pleased to contribute the SYNTAX trial data to the
advancement of evidence-based medicine," said Keith D. Dawkins, M.D.,
Associate Chief Medical Officer of Boston Scientific. "The patients enrolled
in SYNTAX have exceptionally complex anatomy and advanced disease,
representing an unprecedented study group for a stent trial. Ongoing findings
from this study will continue to be used to enhance the value of the SYNTAX
Score in this high-risk patient population."

Boston Scientific will be announcing subset data analyses from the SYNTAX
trial this week at EuroPCR.

The SYNTAX Score and SYNTAX Score website were developed under the direction
of the SYNTAX trial steering committee, chaired by Dr. Serruys and F.W. Mohr,
M.D., Ph.D., and were made possible by support from Boston Scientific and
Cardialysis BV.

The safety and effectiveness of the TAXUS(R) Express2(R) Paclitaxel-Eluting
Coronary Stent System has not been established in patients with left main or
three-vessel disease. The SYNTAX Score and related materials are not intended
to provide medical advice or guidance as to appropriate treatment strategies
for individual patients.

Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words. These
forward-looking statements are based on our beliefs, assumptions and estimates
using information available to us at the time and are not intended to be
guarantees of future events or performance. These forward-looking statements
include, among other things, statements regarding clinical trials, regulatory
approvals, competitive offerings and product performance. If our underlying
assumptions turn out to be incorrect, or if certain risks or uncertainties
materialize, actual results could vary materially from the expectations and
projections expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together with other
factors) could affect our ability to implement our business strategy and may
cause actual results to differ materially from those contemplated by the
statements expressed in this press release. As a result, readers are
cautioned not to place undue reliance on any of our forward-looking
statements.

Factors that may cause such differences include, among other things: future
economic, competitive, reimbursement and regulatory conditions; new product
introductions; demographic trends; intellectual property; litigation;
financial market conditions; and, future business decisions made by us and our
competitors. All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that may
affect our future operations, see Part I, Item 1A- Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A - Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file thereafter. We
disclaim any intention or obligation to publicly update or revise any
forward-looking statements to reflect any change in our expectations or in
events, conditions, or circumstances on which those expectations may be based,
or that may affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary statement is
applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation

Natacha Gassenbach (onsite at PCR)
508-250-9348 (mobile)
33 1 6 08 97 70 36 (mobile)
Media Relations
Boston Scientific Corporation

Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation

SOURCE Boston Scientific Corporation

Media, Paul Donovan, +1-508-650-8541 (office), +1-508-667-5165 (mobile), or
Natacha Gassenbach (onsite at PCR), +1-508-250-9348 (mobile), 33 1 6 08 97 70
36 (mobile); or Investors, Larry Neumann, +1-508-650-8696 (office), all of
Boston Scientific Corporation